Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 8,001.5% | – | – | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 85.6% | 75.5% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -473.3% | -23,321% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -605.1% | -29,558.9% | – | – |
| EPS Diluted | -5.29 | -3.93 | -5.7 | -4 |
| % Growth | -34.6% | 31.1% | -42.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |